Gotu Kola for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Gotu Kola for Health & Longevity

Created on 09/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Active plant compounds act on collagen and small blood vessels. Strongest evidence: leg-vein symptoms and swelling, wrinkle depth, skin water content, wound healing. Weaker signals for nerve symptoms, leg strength, alertness, anxiety. The traditional memory claim is not supported. Harms are mostly mild gastrointestinal upset, skin allergy, rarely liver injury. Most products cannot be matched to what was tested. (Full Review)

Protocol

Standardized triterpene fraction for venous use
120–180 mg/day
60 mg of titrated extract two or three times daily, 4 to 12 weeks
Whole-plant extract for general use
250–750 mg/day
Once daily, 60 to 90 days; strength and mood effects only at 500 mg and above
Best time of day
Divided doses with meals
Where drowsiness occurs, the larger share of a split dose falls in the evening
Time to effect
Venous symptoms
4 to 8 weeks
Leg heaviness, ankle swelling, pain and cramping
Wrinkle depth
8 to 12 weeks
Both topical and oral preparations
Wound and post-procedure effects
Within days
Re-epithelialization, less redness and crusting

Benefits

Contraindications
  • Pregnancy and breastfeeding, at any dose and by any route
  • Active hepatocellular disease, or liver impairment at Child-Pugh Class B or C
  • Alanine aminotransferase or aspartate aminotransferase above twice the upper reference limit at baseline
  • Prior hepatitis attributed to Gotu Kola or to any Apiaceae-family botanical
  • Known allergy to Gotu Kola, asiaticoside, or other Apiaceae plants (celery, carrot, parsley)
  • Scheduled surgery within 14 days
  • Children under 18
    •
Key Interactions
  • Sedatives and central nervous system depressants: benzodiazepines (diazepam), barbiturates (phenobarbital), zolpidem, alcohol
  • Hepatotoxic medications: acetaminophen, methotrexate, isoniazid, amiodarone, high-dose statins (atorvastatin)
  • Glucose-lowering medications: metformin, sulfonylureas (glipizide), insulin
  • Diuretics: furosemide, hydrochlorothiazide
  • Substrates of CYP3A4 and CYP2C9: statins (simvastatin), warfarin, calcium channel blockers (amlodipine)
  • Over-the-counter sedating antihistamines: diphenhydramine, doxylamine, chlorpheniramine
  • Over-the-counter acetaminophen: in cold, flu and pain preparations
  • Sedating and calming supplements: kava, valerian, passionflower, melatonin, ashwagandha, high-dose magnesium
  • Venoactive supplements with additive effects: horse chestnut, diosmin-hesperidin, butcher's broom, pine bark
  • Liver-implicated botanicals: green tea extract, kava, black cohosh, garcinia, comfrey
  • Bacopa monnieri
  • Topical retinoids: tretinoin, adapalene, retinol
    •

Risk & Side Effects

  • High: Gastrointestinal upset
    •
  • Medium: Allergic contact dermatitis; drug-induced liver injury
    •
  • Low: Drowsiness and impaired alertness
    •
  • Speculative: Reproductive and developmental effects
    •

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) 10–26 U/L (men), 7–20 U/L (women) Earliest and most specific signal of liver-cell injury
Aspartate aminotransferase (AST) 10–26 U/L Confirms a liver signal and helps separate liver from muscle origin
Alkaline phosphatase (ALP) 50–90 U/L Distinguishes bile-duct pattern injury from liver-cell pattern
Total bilirubin 0.4–1.2 mg/dL Marks clinically significant liver injury when raised alongside enzymes
Hemoglobin A1c (HbA1c) 4.8–5.4% Detects any drift in average blood glucose over about three months
High-sensitivity C-reactive protein (hs-CRP) Below 0.5 mg/L Tracks the general inflammatory tone the herb is proposed to lower
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73 m² Confirms kidney function is adequate before adding any botanical

Cadence: Liver panel before the first dose, at 8 weeks, then every 6 months, and immediately on any symptom suggesting liver injury; outcome measures at 8 and 12 weeks; eGFR once at baseline

Qualitative Assessment

  • Leg heaviness, aching and cramping at the end of the day, on a 0–10 scale each evening
  • Visible ankle swelling, judged by sock indentation at a consistent time of day
  • Daytime alertness and any new drowsiness, especially in the first fortnight
  • Sleep onset latency and subjective sleep quality
  • Skin texture and hydration, assessed against baseline photographs under consistent lighting
  • Wound or scar appearance where the herb is being used topically
  • Irritability and stress reactivity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.